Zomedica Corp.
ZOMDF Healthcare Medical Devices
Zomedica Corp.’s revenue for fiscal 2025 (year ended December 2025) was $32.0 million, up 17.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.6%, EPS grew 49.3% and free cash flow grew 40.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow ZOMDF
Zomedica Corp. (ZOMDF) EV/Sales
As of 16 October 2026, Zomedica Corp. (ZOMDF) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from −1.5× (March 2025) to 45.5× (March 2022); the current reading is higher than 62% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.4× | (17.55%) |
| FY2024 | 1.7× | (55.13%) |
| FY2023 | 3.8× | 71.26% |
| FY2022 | 2.2× | (90.97%) |
| FY2021 | 24.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | (28.30%) |
| Mar 2026 | 2.1× | 45.55% |
| Dec 2025 | 1.4× | 61.35% |
| Sep 2025 | 0.9× | — |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OM Outset Medical, Inc. compare | 0.2× |
| LUNG Pulmonx Corporation compare | 0.7× |
| ZOMDF Zomedica Corp. | 0.9× |
| LNSR LENSAR, Inc. compare | 1.1× |
| ECOR electroCore, Inc. compare | 1.9× |
| APYX Apyx Medical Corporation compare | 2.2× |
| HYPR Hyperfine, Inc. compare | 2.6× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| SERA Sera Prognostics, Inc. compare | 822× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)